XPhyto Secures Exclusive Psychedelic Drug Development Agreement
The Pharma Data
NOVEMBER 9, 2020
On August 20, 2018, the Company signed the Exclusive Dealing Agreement with Prof. He is also a current member of the Health Canada Scientific Advisory Committee on Pharmaceutical Sciences and Clinical Pharmacology and the Scientific Advisory Panel on Opioid Analgesic Abuse. SOURCE: XPhyto Therapeutics Corp. .
Let's personalize your content